Le Lézard
Classified in: Business
Subjects: SVY, LEG, CPG, CMG

Ontario tobacco taxation is contributing to a growing contraband market


Up to $3.4b in tobacco tax revenue lost to contraband market since 2013

TORONTO, March 8, 2018 /CNW/ - An EY review of tobacco tax policy in Ontario shows tax rate increases are reducing revenue for the province as consumers turn to a growing contraband market.

The provincial government introduced a $3 per carton price increase in February 2016, followed by an additional $2 per carton increase in April 2017 ? with a promise of further $4 per carton increases in both 2018 and 2019. Tax revenue for the province, meanwhile, has fallen short of expectations by $240m over the five-year period from 2013 to 2017.

Research shows that continued tax rate increases are widening the price gap between legal and contraband tobacco. Legal cigarette prices have increased by 15% since Q4 2014. What was then a $54 per carton price gap grew to $66 per carton in Q3 2017.

EY research suggests that additional planned tobacco tax increases by the Government of Ontario will drive that price gap to $78 per carton by the end of 2019. This could divert more legal taxed consumption into the untaxed contraband market instead. Data suggests legal demand will fall by almost 11% in 2018 and an additional 7% in 2019.

Contraband tobacco already represents more than one third (33.8%) of the total market in Ontario. What's more, Ontario accounts for over 80% of the total tobacco contraband market in Canada. This translates into $750m in lost provincial revenue, or "tax gap," per annum.

The EY report suggests that with recent federal and Ontario tobacco tax increases, the province could see revenues fall short of its forecasts by $235m per year in 2018-19 and 2019-20.

Based on these figures, the report recommends the provincial government consider alternative taxation plans and enforcement measures to mitigate the flow of revenue to the contraband market.

About EY
EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.

For more information, please visit ey.com/ca. Follow us on Twitter @EYCanada.

EY refers to the global organization and may refer to one or more of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit ey.com.

SOURCE EY (Ernst & Young)


These press releases may also interest you

at 23:00
Cybervation, an award-winning global technology and healthcare solutions company, proudly announces that its CEO, Purba Majumder, has been distinguished as one of the 2024 100 Women to KNOW Across America. This award from KNOW Women recognizes...

at 22:30
Blue Owl Capital Inc. ("Blue Owl") , a leading alternative asset manager, announced today the hiring of Alicia Gregory as a Managing Director based in Sydney.   Alicia brings over 25 years of investing experience with deep relationships and...

at 22:00
Zetrix Foundation and MY E.G. Services Berhad ("MYEG") signed a Memorandum of Understanding (MoU) with MaiCapital, a licensed virtual asset manager in Hong Kong, to collaborate on the launch of a virtual asset fund or Hong Kong virtual assets...

at 21:38
Grupo Elektra, S.A.B. de C.V. (BMV: ELEKTRA* Latibex: XEKT), Latin America's leading specialty retailer and financial services company, and the largest non-bank provider of...

at 21:30
O2Gold Inc. (NEX: OTGO.H) ("O2Gold" or the "Company") is pleased to announce that it has entered into a share exchange agreement dated March 21, 2024 (the "Agreement") with Quebec Aur Ltd., a private Ontario corporation, (the "Target") and its...

at 21:27
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...



News published on and distributed by: